Bayer PE Ratio 2010-2024 | BAYRY

Current and historical p/e ratio for Bayer (BAYRY) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bayer PE ratio as of April 02, 2025 is 4.39.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Bayer PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
0.00 nan
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $23.657B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $783.103B 63.53
Johnson & Johnson (JNJ) United States $399.649B 16.60
AbbVie (ABBV) United States $370.636B 20.70
Novo Nordisk (NVO) Denmark $311.614B 21.11
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Novartis AG (NVS) Switzerland $227.865B 14.27
Merck (MRK) United States $226.737B 11.75
Pfizer (PFE) United States $143.715B 8.15
Sanofi (SNY) $140.749B 13.33
Innoviva (INVA) United States $1.136B 10.48